Adeno-Associated Virus Vector-Based Gene Therapy Market 2024-32

The Reports and Insights, a leading market research company, has recently releases report titled “Adeno-Associated Virus (AAV) vector-based gene therapy Market Share: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Adeno-Associated Virus (AAV) vector-based gene therapy Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Adeno-Associated Virus (AAV) vector-based gene therapy Market?

The global Adeno-Associated Virus (AAV) vector-based gene therapy market size reached US$ 5.2 billion in 2023. Looking forward, Reports and Insights expects the market to reach US$ 18.4 billion in 2032, exhibiting a growth rate (CAGR) of 15.1% during 2024-2032.

What are Adeno-Associated Virus (AAV) vector-based gene therapy?

Adeno-Associated Virus (AAV) vector-based gene therapy is a treatment method that uses a harmless virus, known as the adeno-associated virus, to deliver therapeutic genes into a patient's cells. This virus is modified to carry specific genetic material, such as a healthy gene to replace a faulty one. The modified virus is then introduced into the patient's body, typically through injections. Once inside the cells, the AAV vector releases the therapeutic gene, which can correct or replace the defective gene responsible for a particular disease. This approach shows promise in treating various genetic disorders and has demonstrated effectiveness in clinical trials for conditions like inherited retinal diseases and specific types of muscular dystrophy.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2196

What are the growth prospects and trends in the Adeno-Associated Virus (AAV) vector-based gene therapy industry?

The adeno-associated virus (AAV) vector-based gene therapy market growth is driven by various factors. The market for Adeno-Associated Virus (AAV) vector-based gene therapy is on a significant growth trajectory, primarily propelled by the increasing adoption of gene therapy for treating genetic disorders and chronic diseases. AAV vectors are highly favored in gene therapy due to their efficient delivery of genetic material to target cells, low immunogenicity, and ability to sustain gene expression over time. Market growth is further driven by advancements in AAV vector design, expanding research and development efforts, and the rising number of clinical trials for gene therapy. Collaborations between pharmaceutical firms and research institutions to innovate new gene therapies also play a crucial role in expanding the AAV vector-based gene therapy market. Hence, all these factors contribute to adeno-associated virus (AAV) vector-based gene therapy market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Gene Therapy Application

• Neurological Disorders

• Ophthalmic Diseases

• Muscular Disorders

• Hematological Disorders

By Adeno-Associated Virus Serotype

• AAV1

• AAV2

• AAV5

• AAV9

By End-User

• Hospitals

• Research Institutes

• Biopharmaceutical Companies

By Therapeutic Area

• Rare Diseases

• Oncology

• Cardiovascular Diseases

• Genetic Disorders

By Region

North America

• United States

• Canada

Europe

• Germany

• United Kingdom

• France

• Italy

• Spain

• Russia

• Poland

• Benelux

• Nordic

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• South Korea

• ASEAN

• Australia New Zealand

• Rest of Asia Pacific

Latin America

• Brazil

• Mexico

• Argentina

Middle East Africa

• Saudi Arabia

• South Africa

• United Arab Emirates

• Israel

• Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

• BioMarin Pharmaceutical

• Roche (Spark Therapeutics)

• Sangamo

• Pfizer

• Sarepta Therapeutics

• Freeline Therapeutics

• Regenxbio

• Amicus Therapeutics

• NightstaRx Ltd.

• Solid Biosciences

• Voyager Therapeutics

• UniQure

• Abeona Therapeutics

• Aldevron (acquired by Danaher)

• Oxford BioMedica

View Full Report: https://www.reportsandinsights.com/report/adeno-associated-virus-aav-vector-based-gene-therapy-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd.

1820 Avenue M, Brooklyn, NY, 11230, United States

Contact No: +1-(347)-748-1518

Email: [email protected]

Website: https://www.reportsandinsights.com/

Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/

Follow us on twitter: https://twitter.com/ReportsandInsi1